title: Genotype-guided dosing of warfarin.
authors.affiliation: Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. jmega@partners.org.
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Mega
authors.affiliation: Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
mesh_terms: D000925:Anticoagulants / Q000819:agonists*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy; D002986:Clinical Trials as Topic; D065729:Cytochrome P-450 CYP2C9; D016903:Drug Monitoring; D005838:Genotype; D006801:Humans; D019934:International Normalized Ratio; D054556:Venous Thromboembolism / Q000097:blood / Q000188:drug therapy; D064417:Vitamin K Epoxide Reductases / Q000235:genetics; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases